Literature DB >> 11034869

Epilepsy after the first drug fails: substitution or add-on?

P Kwan1, M J Brodie.   

Abstract

When and how a combination of antiepileptic drugs (AEDs) should be used in patients unresponsive to monotherapy is not known. We followed up prospectively 248 patients in whom treatment with the first AED was unsuccessful. When treatment failed due to intolerable adverse events, a second (substituted) drug was prescribed. When failure was due to lack of efficacy, either AED substitution or combination (add-on) was undertaken. Patients were considered to be seizure-free if they had no seizures for at least 1 year. Among patients with inadequate seizure control on the first well tolerated AED, those who received substituted monotherapy (n= 35) and those who received add-on treatment (n= 42) had similar seizure-free rates (substitution vs. add-on: 17% vs. 26%) and incidence of intolerable side effects (substitution vs. add-on: 26% vs. 12%). Based on the drugs' perceived primary mode of action, more patients became seizure-free when the combination involved a sodium channel blocker and a drug with multiple mechanisms of action (36%) compared to other combinations (7 %, P= 0.05). None of the 11 patients who received add-on treatment after a second drug had also failed became seizure-free, compared to 26% in those who received add-on as soon as the first tolerated AED proved to be ineffective (n= 42, P= 0.05). These preliminary observations have generated verifiable hypotheses regarding the early management of epilepsy. A randomized study comparing substitution and combination after the failure of the first AED is underway. Copyright 2000 BEA Trading Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034869     DOI: 10.1053/seiz.2000.0442

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  58 in total

Review 1.  Place of polytherapy in the early treatment of epilepsy.

Authors:  Charles L P Deckers
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Ketone bodies in epilepsy.

Authors:  Melanie A McNally; Adam L Hartman
Journal:  J Neurochem       Date:  2012-02-07       Impact factor: 5.372

Review 3.  Update on anticonvulsant drugs.

Authors:  Derek J Chong; Carl W Bazil
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

4.  The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life.

Authors:  Erik K St Louis
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-01

Review 5.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 6.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

7.  Epilepsy surgery: recommendations for India.

Authors:  P Sarat Chandra; Manjari Tripathi
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

8.  Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.

Authors:  William R Garnett; Erik K St Louis; Thomas R Henry; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

9.  Monotherapy to polytherapy: antiepileptic drug conversions through the spectrum of epilepsy care.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

10.  Antiepileptic drug monotherapy: the initial approach in epilepsy management.

Authors:  Erik K St Louis; William E Rosenfeld; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.